期刊
EXPERT OPINION ON THERAPEUTIC PATENTS
卷 19, 期 10, 页码 1449-1453出版社
INFORMA HEALTHCARE
DOI: 10.1517/13543770903185920
关键词
acylsulfamides; anticonvulsant; bioisostere; carbonic anhydrase; chemokine receptor; endothelin receptor antagonists; monoamine uptake inhibitors; potassium channels; PPAR-alpha agonists; sulfamide; sulfonamide; therapeutic
Background: The sulfamide (R(2)NSO(2)NR(2)) functionality is an acceptable functional group in medicinal chemistry when incorporated into putative small-molecule therapeutics, as it has the potential to form several electrostatic interactions with protein and other targets. The clinically-useful broad spectrum antibiotic doripenem contains a mono-substituted sulfamide. The sulfamide functional group is often found to substitute for sulfonamide, sulfamate or urea functionality. Objective/method: During the period of 2006 - 2008, there were nine published patents in which all or most reported compounds contained the sulfamide functional group. There are also patents in which the structures disclosed contain a cyclic sulfamide functional group. Further, there are patents published during this time-frame that contain only a few sulfamide-containing examples, typically as a bioisosteric replacement for a sulfonamide moiety. in this review, we focus on those published patents in which most compounds disclosed are sulfamides and only briefly highlight examples in which sulfamides are included among a large list of other suitable functionalities. Conclusion: While the sulfamide functionality is still fairly under-represented in medicinal chemistry it is a valuable and versatile group that will gain increasing acceptance and favor in the future.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据